Selumetinib Yields Modest Benefits in Rare Eye Cancer

June 19, 2014

Tara C. Gangadhar, MD, assistant professor in the division of Hematology/Oncology at the Abramson Cancer Center, spoke to Medscape about a new study investigating the use of the MEK inhibitor selumetinib in uveal melanoma. Tumor responses were better and progression-free survival time was longer with the drug over chemotherapy—but there was no benefit to overall survival. This "confirms that this drug does have activity in uveal melanoma; however, we need to continue to make clinical advances to improve outcomes in these patients," Gangadhar said. "The high rate of adverse events is similar to that seen with other targeted therapies; the toxicities were mild and were manageable in most patients.”

Medscape article